Skip to content

OS Therapies OSTX Chief Operating Decision Maker — Other Nonoperating Income

Similar metrics at other companies

Sionna Therapeutics, Inc. Common Stock logo
SIONOther Nonoperating Income
$0-100%
Vor Biopharma logo
VOROther Nonoperating Income
$2K
JBT Marel Corporation logo
JBTMOther Nonoperating Income
$2M0.0%
Virtuix Holdings Inc.
 logo
VTIXOther Nonoperating Income
$1.36K
Cato Corporation logo
CATOOther Nonoperating Income
$444.75K+28.1%
American Battery Technology Company logo
ABATOther Nonoperating Income
$233.74K+437%

Other financials

Income statement

See full
Operating income-$10.2M-103%
Net income-$10.4M-168%
EPS (diluted)-$0.27-50.0%

Balance sheet

See full
Cash & equivalents$917.6K-69.1%
Total debt$20.0M
Total equity-$10.8M-159%
Total assets$7.3M+71.7%

Cash flow

See full
Operating cash flow-$4.6M-32.6%
CapEx$316.4K
Free cash flow-$3.7M

Valuation

See full
Market cap$84.62M+65.5%
Enterprise value$103.7M

Returns & leverage

See full
Return on equity470%
Debt / equity-1.8×
Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncome.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's chief operating decision maker — other nonoperating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OS Therapies's chief operating decision maker — other nonoperating income?
OS Therapies (OSTX) reported chief operating decision maker — other nonoperating income of -$75.34K in Q1 2026.
How has OS Therapies's chief operating decision maker — other nonoperating income changed year-over-year?
OS Therapies's chief operating decision maker — other nonoperating income decreased by 114257.6% year-over-year, from $66 to -$75.34K.
What does chief operating decision maker — other nonoperating income mean?
Includes miscellaneous income streams that are not derived from the company's core clinical development or commercial operations. This may include gains from asset disposals or other peripheral financial activities. It provides a view of secondary income sources that impact the bottom line.